Torthaí cuardaigh - Fangling Ning

The “Hand as Foot” teaching method in lymph-node staging of breast cancer de réir Xiaole Wang, Fangling Ning, Zhenbo Wang, Miaolong He

Faigh an téacs iomlán

Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review de réir Mingyue Wang, Hongzhi Liu, Ruixin Zhang, Runyu Li, Xiaoyu Qin, Fangling Ning, Lijun Tian

Faigh an téacs iomlán

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC de réir Yanzhang Hao, Jianwei Liu, Ping Wang, Feng Wang, Zeshun Yu, Mianli Li, Shaoshui Chen, Fangling Ning

Faigh an téacs iomlán

First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observation... de réir Bo Zhang, Fangling Ning, Xiaomei Liu, Na Li, Pingfei Wang, Wenxiu Yao, Baohui Han, Qiming Wang, Hua Zhong

Faigh an téacs iomlán

Metal-based nanomaterials for cancer phototherapy: current advancements and translational challenges de réir Hao Su, Xinyu Zhao, Wenchao Xu, Huanlan Sa, Xiaohan Li, Zhibing Liu, Fangling Ning, Mianli Li, Zhijing He

Faigh an téacs iomlán

Multi-omics analysis and experiments uncover the function of cancer stemness in ovarian cancer and establish a machine learning-based model for predicting immunotherapy responses de réir Zhibing Liu, Zhibing Liu, Lei Han, Xiaoyu Ji, Xiaole Wang, Jinbo Jian, Yujie Zhai, Yingjiang Xu, Feng Wang, Xiuwen Wang, Fangling Ning

Faigh an téacs iomlán

lncRNA IGFL2-AS1 mediates NSCLC chemoresistance via YBX1-induced HSPA1A/RAP1 activation de réir Hongliang Dong, Yunxiu Xia, Jingjing Qi, Cuilan Liu, Fei Wang, Bingjie Cui, Weiwei Chen, Wenwen Lv, Nailiang Zhai, Jiong Deng, Yong Yu, Fangling Ning, Clemens A. Schmitt, Jing Du

Faigh an téacs iomlán

Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a mul... de réir Chuanhua Zhao, Jun Zhao, Yigui Chen, Bo Liu, Yangfeng Du, Chenglin Li, Jingdong Zhang, Mudan Yang, Ying Liu, Yuxian Bai, Suyi Li, Ruixing Zhang, Fangling Ning, Yanping Liu, Kai Zou, Qi Zhang, Yijiao Xie, Yuping An, Jianming Xu

Faigh an téacs iomlán

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial de réir Yongmei Yin, Qingyuan Zhang, Tao Sun, Chunfang Hao, Zhihong Wang, Jin Yang, Yongsheng Wang, Yanxia Shi, Jing Sun, Quchang Ouyang, Haichuan Su, Jinsheng Wu, Lu Gan, Meng Han, Liming Gao, Xiaojia Wang, Bing Zhao, Hui Li, Jiuda Zhao, Hongwei Yang, Fangling Ning, Fuguo Tian, Juliang Zhang, Hongmei Sun, Zhaofeng Niu, Hong Zong, Aimin Zang, Xinshuai Wang, Xinyu Qian, Shikai Wu, Jianyun Nie, Lijia He, Ying Cheng, Yanrong Hao, Yi Zhai, Huiping Li, Jingfen Wang, Shihong Wei, Man Li, Yunjiang Liu, Hongqiang Guo, Qun Hu, Lina Liu, Xinghua Han, Ruizhen Luo, Mingli Ni, Xianjun Tang, Zhenhua Zhai, Meiqian Ding, Haibo Wang, Peng Shen, Xian Wang, Lian Liu, Wenyan Chen, Gang Liu, Zhengwen Cai, Zefei Jiang

Faigh an téacs iomlán